Kinase Inhibitor Discovery
with an untiring quest for future therapeutics

FY2023 Q1 Presentation

Consolidated Financial Results for the First Quarter of the Year Ending December 31, 2023

Corporate Presentation Feb. 2023

Carna Biosciences Regains Exclusive Development and Commercialization Rights to AS-1763 in Greater China

Corporate Presentation Feb. 2023

FY2022 Presentation

Consolidated Financial Results for the Year Ended December 31, 2022

Carna Initiates Dosing in the MAD Part of Phase 1 Trial of AS-0871